Wednesday, March 18th
6:00 - 7:00 pm | Reception to Follow

Broad Institute Auditorium + Discovery Center
415 Main Street, Cambridge, MA

In the early 2000s, Broad Institute researchers found that the EGFR protein is mutated in lung cancer, sparking a revolution in targeted cancer treatment. But not all lung tumors respond to such treatments, leaving many patients with few options. In this Broad Discovery Series event, Heidi Greulich and Matthew Meyerson will describe the 20-year history of sevabertinib, a new lung cancer drug (and the first FDA-approved drug born of Broad science) that blocks both EGFR and the related HER2 protein; talk about the unmet need it fulfills, discuss the unique partnership behind its development, and explore drug development's evolving challenges.

To attend virtually, follow the link here at the time of the event.